Treatment-resistant depression may yield to combinations of medications already in clinical use

New research published in JAMA Psychiatry indicates that combinations of medications already approved for clinical use may offer effective treatment options for patients with treatment-resistant depression.

Researchers from Harvard, Yale, and the University of Toronto analyzed existing clinical trials involving patients with depression unresponsive to conventional treatments. They found that combining antidepressants with certain antipsychotics can significantly reduce depressive symptoms. Notably, some antipsychotics, such as lumapeterone, showed high efficacy but were also associated with higher discontinuation rates due to side effects.

Additionally, a separate study examined intravenous ketamine, a drug originally developed as an anesthetic, and found it to be effective in rapidly reducing suicidal impulses and depressive symptoms over short periods. Ketamine’s efficacy was comparable to esketamine, a nasal spray approved by the FDA for depression treatment, especially in acute settings.

Why It Matters

This development could expand treatment options for the approximately one-third of adults with depression who do not respond to standard antidepressants. By identifying effective medication combinations, clinicians may improve outcomes for these patients, potentially reducing suicide risk and improving quality of life.

Background

Treatment-resistant depression affects a significant portion of the population, with many patients failing to find relief through existing therapies. Prior research has explored novel approaches such as ketamine infusions and esketamine nasal spray. These recent studies build on that foundation by evaluating the efficacy of combining existing drugs, which could streamline treatment implementation and approval processes.

“These studies could potentially guide practicing psychiatrists and other clinicians to consider these new approaches of modalities for patients with moderate to severe depression, who did not previously respond to conventional antidepressant therapies.”

— T. Greg Rhee, UConn School of Medicine psychiatric epidemiologist

“We plan to conduct population-level epidemiologic studies to further examine the effectiveness and safety profiles of these treatment options.”

— Rhee

What Remains Unclear

It remains unclear which specific medication combinations will be most effective and safest across diverse patient populations. Long-term safety data and large-scale clinical trials are still needed to confirm these preliminary findings.

What’s Next

Next steps include conducting large-scale epidemiologic and clinical studies to evaluate the safety, efficacy, and tolerability of these medication combinations. Regulatory agencies may also review existing drugs for new indications based on these findings.

Key Questions

Can these medication combinations be used immediately for treatment-resistant depression?

Not yet. While the findings are promising, further clinical trials are necessary before these combinations can be widely recommended or approved for routine use.

Are these treatments safe long-term?

Long-term safety profiles are still under investigation. Ongoing studies aim to assess potential side effects and risks associated with these medication combinations over extended periods.

How do these findings change current treatment options?

They suggest that existing medications, when combined appropriately, may provide new avenues for treating patients who do not respond to standard antidepressants, potentially leading to updated clinical guidelines.

What is the role of ketamine in these new approaches?

Ketamine, administered intravenously, has shown rapid short-term benefits in reducing suicidal impulses and depressive symptoms, but its long-term efficacy and safety are still under study.